What's in Shanghai Kechow Pharma, Inc.'s pipeline?

Shanghai Kechow Pharma, Inc. has 4 drugs in our index: 0 marketed, 0 filed, 1 in Phase 3, 1 in Phase 2, 2 in Phase 1.

Which companies overlap with Shanghai Kechow Pharma, Inc.'s portfolio?

Top competitors by shared drug class: Pierre Fabre Medicament.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/shanghai-kechow-pharma-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Shanghai Kechow Pharma, Inc. — Portfolio Competitive Intelligence Brief

Shanghai Kechow Pharma, Inc. pipeline: 0 marketed, 0 filed, 1 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 1 Phase 2 2 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Tunlametinib plus Vemurafenib	Tunlametinib plus Vemurafenib	phase 3	BRAF inhibitor + MEK inhibitor combination	BRAF V600E and MEK1/2	Oncology

Therapeutic area mix

Oncology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Pierre Fabre Medicament · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Shanghai Kechow Pharma, Inc.:

Cite this brief

Drug Landscape (2026). Shanghai Kechow Pharma, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/shanghai-kechow-pharma-inc. Accessed 2026-05-16.